A single-patient study conducted by British scientists found that Gilead’s remdesivir could be highly effective against Covid-19, raising questions about previous studies that found the antiviral drug had no impact on death rates from the disease.

Relay Therapeutics entered a global license and collaboration agreement with Genentech for the commercialization and development of RLY-1971, a potent inhibitor of SHP2.

German biotech firm CureVac enrolled the first participant for a Phase 2b/3 clinical trial of the company’s Covid-19 vaccine candidate.

A clinical trial of the widely used antibiotic azithromycin in hospitalized Covid-19 patients found no convincing evidence of benefit, prompting doctors to announce that they have closed that section of the trial.

Novartis said a late-stage clinical trial of ruxolitinib on top of standard therapy showed no significant reduction in severe complications of Covid-19, including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit.

A U.S. Centers for Disease Control and Prevention advisory panel on Dec. 12 recommended the nation’s first COVID-19 vaccine, helping clear the way for public health authorities to begin the largest vaccination campaign in U.S. history.

Top U.S. Food and Drug Administration regulators said most Americans with allergies should be safe to receive the Covid-19 vaccine developed by Pfizer Inc. and Germany’s Biotech SE.

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration authorized the emergency use of the mRNA vaccine, BNT162b2, against Covid-19 in individuals 16 years of age or older.

Four more companies secured their place on the stock ticker in a record-breaking year before 2020 comes to a close.  

A Covid-19 vaccine being developed by CSL Ltd. and the University of Queensland was scrapped after numerous vaccine recipients reported receiving false positives on certain HIV tests, according to the Wall Street Journal.